{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:04:31Z","timestamp":1788447871147,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Charit\u00e9 Publikationsfond"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01558-0","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:36:35Z","timestamp":1759973795000},"page":"3651-3670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Determinants of Satisfaction with Medical Care for Hidradenitis Suppurativa: Results from a Multicentre Survey in Germany"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7689-4130","authenticated-orcid":false,"given":"Kerstin","family":"Wolk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Wilsmann-Theis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nessr Abu","family":"Rached","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Cugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotraut","family":"Moessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kromer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk G.","family":"Bechara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke K.","family":"Peitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa C.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Happ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Siddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Kubitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durdana","family":"Gro\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Vandersee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khusru","family":"Asadullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylke","family":"Schneider-Burrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Kokolakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sabat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"10476","key":"1558_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","volume":"405","author":"R Sabat","year":"2025","unstructured":"Sabat R, Alavi A, Wolk K, et al. Hidradenitis suppurativa. Lancet. 2025;405(10476):420\u201338.","journal-title":"Lancet"},{"issue":"6","key":"1558_CR2","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/bjd.19435","volume":"183","author":"JR Ingram","year":"2020","unstructured":"Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):990\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1558_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak L, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"1558_CR4","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1159\/000520262","volume":"238","author":"S Moloney","year":"2022","unstructured":"Moloney S, McGrath BM, Roshan D, Gethin G. The personal impact of daily wound care for hidradenitis suppurativa. Dermatology. 2022;238(4):762\u201371.","journal-title":"Dermatology"},{"issue":"3","key":"1558_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaad.2019.11.068","volume":"83","author":"KR Patel","year":"2020","unstructured":"Patel KR, Lee HH, Rastogi S, et al. Association between hidradenitis suppurativa, depression, anxiety, and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;83(3):737\u201344.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1558_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/jdv.16726","volume":"35","author":"C Cuenca-Barrales","year":"2021","unstructured":"Cuenca-Barrales C, Montero-Vilchez T, Szepietowski JC, Matusiak L, Molina-Leyva A. Sexual impairment in patients with hidradenitis suppurativa: a systematic review. J Eur Acad Dermatol Venereol. 2021;35(2):345\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1558_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jaad.2011.10.024","volume":"67","author":"A Kurek","year":"2012","unstructured":"Kurek A, Peters EM, Chanwangpong A, Sabat R, Sterry W, Schneider-Burrus S. Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol. 2012;67(3):422\u20138 (8e1).","journal-title":"J Am Acad Dermatol"},{"key":"1558_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.676241","volume":"8","author":"S Schneider-Burrus","year":"2021","unstructured":"Schneider-Burrus S, Tsaousi A, Barbus S, et al. Features associated with quality of life impairment in hidradenitis suppurativa patients. Front Med. 2021;8:676241.","journal-title":"Front Med"},{"issue":"5","key":"1558_CR9","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/bjd.20523","volume":"185","author":"L Howells","year":"2021","unstructured":"Howells L, Lancaster N, McPhee M, et al. Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review. Br J Dermatol. 2021;185(5):921\u201334.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1558_CR10","first-page":"34","volume":"11","author":"PK Krajewski","year":"2021","unstructured":"Krajewski PK, Matusiak L, von Stebut E, et al. Quality-of-life impairment among patients with hidradenitis suppurativa: a cross-sectional study of 1795 patients. Life (Basel). 2021;11(1):34.","journal-title":"Life (Basel)."},{"issue":"1","key":"1558_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/bjd\/ljac027","volume":"188","author":"S Schneider-Burrus","year":"2023","unstructured":"Schneider-Burrus S, Kalus S, Fritz B, Wolk K, Gomis-Kleindienst S, Sabat R. The impact of hidradenitis suppurativa on professional life. Br J Dermatol. 2023;188(1):122\u201330.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1558_CR12","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/bjd.17578","volume":"180","author":"H Tiri","year":"2019","unstructured":"Tiri H, Jokelainen J, Timonen M, Tasanen K, Huilaja L. Substantially reduced life expectancy in patients with hidradenitis suppurativa: a Finnish nationwide registry study. Br J Dermatol. 2019;180(6):1543\u20134.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1558_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamadermatol.2019.3412","volume":"156","author":"S Reddy","year":"2020","unstructured":"Reddy S, Strunk A, Jemec GBE, Garg A. Incidence of myocardial infarction and cerebrovascular accident in patients with hidradenitis suppurativa. JAMA Dermatol. 2020;156(1):65\u201371.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1558_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031810","volume":"7","author":"R Sabat","year":"2012","unstructured":"Sabat R, Chanwangpong A, Schneider-Burrus S, Metternich D, Kokolakis G, Kurek A, et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS ONE. 2012;7(2):e31810.","journal-title":"PLoS ONE"},{"issue":"12","key":"1558_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1089\/jir.2023.0105","volume":"43","author":"R Sabat","year":"2023","unstructured":"Sabat R, Gudjonsson JE, Brembilla NC, van Straalen KR, Wolk K. Biology of interleukin-17 and novel therapies for hidradenitis suppurativa. J Interferon Cytokine Res. 2023;43(12):544\u201356.","journal-title":"J Interferon Cytokine Res"},{"issue":"5","key":"1558_CR16","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1558_CR17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/bjd\/ljad135","volume":"189","author":"M Schultheis","year":"2023","unstructured":"Schultheis M, Staubach P, Nikolakis G, et al. A centre-based ambulatory care concept for hidradenitis suppurativa improves disease activity, disease burden and patient satisfaction: results from the randomized controlled EsmAiL trial. Br J Dermatol. 2023;189(2):170\u20139.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1558_CR18","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/bjd\/ljad454","volume":"190","author":"HE Wainman","year":"2024","unstructured":"Wainman HE, Chandran NS, Frew JW, et al. Global consensus process to establish a core dataset for hidradenitis suppurativa registries. Br J Dermatol. 2024;190(4):510\u20138.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1558_CR19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/bjd.17537","volume":"180","author":"JR Ingram","year":"2019","unstructured":"Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019;180(5):1009\u201317.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1558_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334.","journal-title":"N Engl J Med"},{"issue":"10378","key":"1558_CR21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747\u201361.","journal-title":"Lancet"},{"issue":"10443","key":"1558_CR22","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504\u201319.","journal-title":"Lancet"},{"issue":"5 Suppl 1","key":"1558_CR23","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.jaad.2015.07.049","volume":"73","author":"R Alhusayen","year":"2015","unstructured":"Alhusayen R, Shear NH. Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S42\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"1558_CR24","doi-asserted-by":"crossref","unstructured":"Wolk K, Cugno G, Kokolakis G, et al. Low satisfaction with medical care among patients with hidradenitis suppurativa: a multicenter study. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.20718","DOI":"10.1111\/jdv.20718"},{"key":"1558_CR25","doi-asserted-by":"crossref","unstructured":"Ingram JR, Bettoli V, Espy JI, et al. Treatment satisfaction in patients with hidradenitis suppurativa: a real-world survey from the EU5 and US. Dermatology. 2025;241(2):149\u201361.","DOI":"10.1159\/000542343"},{"issue":"6","key":"1558_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/bjd.21798","volume":"187","author":"B Midgette","year":"2022","unstructured":"Midgette B, Strunk A, Akilov O, et al. Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project. Br J Dermatol. 2022;187(6):927\u201335.","journal-title":"Br J Dermatol"},{"key":"1558_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1384055","volume":"11","author":"K Wolk","year":"2024","unstructured":"Wolk K, Schielein M, Maul JT, et al. Patient-reported assessment of medical care for chronic inflammatory skin diseases: an enterprise-based survey. Front Med. 2024;11:1384055.","journal-title":"Front Med"},{"issue":"5","key":"1558_CR28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/bjd\/ljad215","volume":"189","author":"Y Sow","year":"2023","unstructured":"Sow Y, Salame N, Siira MR, et al. Healthcare experiences among patients with hidradenitis suppurativa: a qualitative study. Br J Dermatol. 2023;189(5):624\u20136.","journal-title":"Br J Dermatol"},{"issue":"10275","key":"1558_CR29","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","volume":"397","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Balato A, Enerback C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754\u201366.","journal-title":"Lancet"},{"issue":"9","key":"1558_CR30","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s00403-023-02645-y","volume":"315","author":"SA Chadha","year":"2023","unstructured":"Chadha SA, Stout MA, Goyal PK, Nguyen CV, Lu KQ. Assessing unmet needs in patients with hidradenitis suppurativa. Arch Dermatol Res. 2023;315(9):2555\u201360.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"1558_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, Neuren E, Cha D, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) project. J Am Acad Dermatol. 2020;82(2):366\u201376.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1558_CR32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","volume":"236","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis G, Wolk K, Schneider-Burrus S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236(5):421\u201330.","journal-title":"Dermatology"},{"issue":"1","key":"1558_CR33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106\u201315.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1558_CR34","first-page":"35","volume":"15","author":"S Chawla","year":"2022","unstructured":"Chawla S, Toale C, Morris M, Tobin AM, Kavanagh D. Surgical management of hidradenitis suppurativa: a narrative review. J Clin Aesthet Dermatol. 2022;15(1):35\u201341.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1558_CR35","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2021.0051","author":"F Collier","year":"2021","unstructured":"Collier F, Howes R, Rodrigues J, Thomas KS, Leighton P, Ingram JR. Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs. BJGP Open. 2021. https:\/\/doi.org\/10.3399\/BJGPO.2021.0051.","journal-title":"BJGP Open"},{"issue":"2","key":"1558_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40271-022-00614-7","volume":"16","author":"D Willems","year":"2023","unstructured":"Willems D, Hinzpeter EL, Van der Zee HH, et al. Patient preferences in the management of Hidradenitis Suppurativa: results of a multinational discrete choice experiment in Europe. Patient. 2023;16(2):153\u201364.","journal-title":"Patient"},{"issue":"2","key":"1558_CR37","doi-asserted-by":"publisher","first-page":"323 e10","DOI":"10.1016\/j.jid.2024.04.035","volume":"145","author":"A McDonald","year":"2025","unstructured":"McDonald A, Karnik R, Campbell V, et al. IRAK4 Is overexpressed in hidradenitis suppurativa skin and correlates with inflammatory biomarkers. J Investig Dermatol. 2025;145(2):323 e10-323 e10.","journal-title":"J Investig Dermatol"},{"issue":"3","key":"1558_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100483","volume":"4","author":"T Leeuw","year":"2025","unstructured":"Leeuw T, Simaite D, Heyninck K, et al. Combined TNF-alpha and OX40L targeting as a new treatment option for hidradenitis suppurativa. J Allergy Clin Immunol Glob. 2025;4(3):100483.","journal-title":"J Allergy Clin Immunol Glob"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01558-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01558-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01558-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:22:07Z","timestamp":1763198527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01558-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1558"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01558-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kerstin Wolk has received research grants or contracts for clinical trials (payment to her institution), support for attending congresses and scientific awards, honoraria for consulting or participation on advisory boards or honoraria for lectures from one or more of the following: Celgene\/Amgen, Celgene\/Bristol Myers Squibb, Charit\u00e9 Research Organization, Flexopharm, Janssen-Cilag, Novartis Pharma, Sanofi\u2013Aventis, TFS Trial Form Support, University hospital Magdeburg, European HS foundation (EHSF) and the Symposium on Hidradenitis Suppurativa Advances (SHSA); she also has a non-financial relationship with the HS task force of the German Consortium for Dermatological Research (ADF). Dagmar Wilsmann-Theis has been an advisor, speaker or investigator for Abbvie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Hexal, Incyte, Janssen-Cilag, Leo Pharma, Eli Lilly, Medac, Merck Sharp & Dohme Corp., MoonLake, Novartis, Pfizer and UCB Pharma. Nessr Abu Rached received funding, travel support and\/or personal honoraria for lectures from Novartis Pharma, Janssen-Cilag GmbH and Johnson & Johnson that were independent of the work submitted. Rotraut M\u00f6ssner has been an advisor and\/or received speakers\u2019 honoraria and\/or received grants and\/or participated in clinical trials of the following companies: Abbvie, Allmirall, Biogen IDEC GmbH, B\u00f6hringer-Ingelheim, Celgene, Janssen-Cilag GmbH, Leo Pharma GmbH, Eli Lilly and Company, Merck Serono GmbH, MSD SHARP & DOHME GmbH, Novartis Pharma GmbH, Pfizer GmbH and UCB. Christian Kromer has been an advisor and\/or received speaker\u2019s honoraria from AbbVie, Janssen-Cilag, Novartis, Almirall, Boehringer Ingelheim and Dermapharm. Falk G. Bechara has received honoraria for participation on advisory boards, in clinical trials and\/or as a speaker from AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Acelyrin, Avalo, Beiersdorf, Boehringer Ingelheim Pharma GmbH & Co. KG, Celltrion, Dr. Wolff, Incyte Corporation, JanssenCilag GmbH,Johnson & Johnson, Merck, M\u00f6lnlycke, MoonLake, Novartis Pharma GmbH,Sanofi, Sitala and UCB Pharma. Katharina Assaf has received financial support (reimbursement of travel expenses and\/or grants and\/or participation in clinical trials) from the following companies: Abbvie, Almirall-Hermal, Amgen, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Incyte, Janssen-Cilag, Leo, Lilly, Novartis, Pfizer, Sanofi, Butterfly IQ and UCB. Wiebke K. Peitsch served as advisory board member for and\/or obtained speakers\u2019 honoraria from and\/or received support for attending meetings from and\/or obtained support for conferences at her institution from and\/or participated in clinical trials by the following companies: AbbVie, ALK-Abello, Almirall Hermal, Amgen, Beiersdorf, Biogen, BMS, Boehringer Ingelheim, Celgene, Dermapharm, Dermasence, Galderma, GSK, Immunocore, Janssen-Cilag, Kyowa Kirin, L\u2019Or\u00e9al, La Roche Posay, LEO Pharma, Lilly, MSD, Mylan, Novartis, Pfizer, Pierre Fabre, Regeneron, Roche, Sanofi, Sun Pharma, UCB Pharma and Viatris. Lisa C. Schneider obtained support for attending congresses and\/or speaker`s honoraria from AbbVie, Janssen-Cilag and UCB Pharma. Durdana Gross was an advisor for, received speakers\u2019 honoraria and\/or grants from and\/or participated in clinical trials for AbbVie, Almirall, Beiersdorf AG, Biogen, Bristol Myers Squibb, Celgene, Galderma, Janssen-Cilag GmbH, LEO Pharma, MSD, Pfizer, Sanofi-Aventis and UCB Pharma. Markus Friedrich received honoraria for participation on advisory boards, in clinical trials or as speaker from the following: Abbvie, Almirall, Bristol-Myers Squibb, Emphasis, Galderma, Janssen, LEO, Novartis, Sanofi Genzyme, UCB and Viatris. Khusru Asadullah received honoraria for participation on advisory boards, consultation, in clinical trials or as a speaker from: Abbvie, Almirall, Antabio, Bayer, Biofrontera, Celltrion, Bristol-Myers Squibb, Euroimmune, Emphasis, Emeritipharma, Galderma, Hexal, Janssen, La Roche-Posay, LEO, L\u2019Or\u00e9al, Novartis, Parexel International, Pierre Fabre, Roxall, RG, Sandoz, Sanofi Genzyme, TFS Trial Form Support and UCB. Sylke Schneider-Burrus has been an advisor for and\/or received speakers\u2019 honoraria from and\/or received grants from and\/or participated in clinical trials of the following companies: Abbvie, Biogen IDEC GmbH, B\u00f6hringer-Ingelheim, Moonlake Immunotherapeutics, Novartis Pharma GmbH, Sanofi-Aventis and UCB. Georgios Kokolakis has received travel grants or honoraria from, or has been a consultant member of advisory boards and speakers bureaus for one or more of the following: AbbVie Deutschland GmbH & Co. KG, Actelion Pharmaceuticals Ltd., Almirall S.A., Amgen GmbH, Basilea Pharmaceutica Ltd., Bayer Schering Pharma AG, Biogen Idec GmbH, Celgene GmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Hexal-Sandoz GmbH, Janssen-Cilag GmbH, Leo Pharma GmbH, Lilly Deutschland GmbH, MSD Sharp & Dohme GmbH, Novartis, Pfizer Deutschland GmbH, Sanofi Deutschland, Takeda, and UCB Pharma GmbH. Robert Sabat has received research grants or clinical trial contracts from AbbVie, Boehringer Ingelheim Pharma, Celgene\/Amgen, Celgene\/Bristol Myers Squibb, Charit\u00e9 Research Organization, CSL Behring, ICON, IQVIA RDS, Incyte, Janssen-Cilag\/Janssen Research and Development, MoonLake Immunotherapeutics, Novartis, Parexel, Rheinischen Friedrich-Wilhelms-Universit\u00e4t Bonn, Sanofi Aventis, TFS and UCB Biopharma paid to their institution; honoraria for lectures, consulting or participation in advisory boards from AbbVie, Almirall Hermal, Amgen, Bayer Schering Pharma, Bruno Bloch Stiftung, Janssen-Cilag\/Janssen Research and Development, Novartis, UCB Biopharma, Universit\u00e4tsmedizin Greifswald, and Wundnetz Berlin-Brandenburg; and is a member of the International Psoriasis Council (unpaid) and speaker of the Psoriasis group of the German Consortium for Dermatological Research (unpaid). Giorgia Cugno, Andreas Happ, Valentina Siddi, Diana Kubitzki and Staffan Vandersee report no conflict of interest regarding this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The survey was approved by the ethics committee of the Charit\u00e9 University Medicine (reference number: EA4\/205\/22, positive vote from 8 February 2023) and registered in the German Register of Clinical Trials (identification number: DRKS00031572). It was conducted in accordance with the Declaration of Helsinki of 1964 and its later amendments. Participation was voluntary and anonymous, and all patients provided informed consent. The survey was conducted between May 2023 and July 2024.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}